Table 5 Resource Utilization among Cancer Patients with Empiric Fluconazole Antifungal Therapy by Treatment Failure
From: Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia
| Treatment Failure | No Treatment Failure | Difference | P | R 2 | |
|---|---|---|---|---|---|
| N | 42 | 61 | |||
| LOS, day | |||||
| Unadjusted Mean (SE) | 30.3 (1.9) | 23.7 (1.5) | 6.6 | 0.007 | |
| Median (range) | 27 (8–73) | 22 (4–55) | 5.0 | ||
| Adjusted Mean (SE) * | 30.7 (1.6) | 23.4 (1.3) | 7.3 | 0.001 | 0.34 |
| Total Costs per patient, $ | |||||
| Unadjusted Mean (SE) | 71,122 (6,432) | 55,234 (5,337) | 15,888 | 0.060 | |
| Median (range) | 56,924 (10,647–275,130) | 47,642 (3,416–268,447) | 9,282 | ||
| Adjusted Mean (SE) * | 72,921 (6,118) | 53,996 (5,068) | 18,925 | 0.020 | 0.18 |
